Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retagliptin Plus Henagliflozein Added to Metformin in T2DM
NCT04667143Phase 3Unknown
- Sponsor
- Hengrui
- Start
- Jan 2021
- Primary completion
- Sep 2022
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of retagliptin, henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Status: unknown.
02
Drugs
retagliptinhenagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04667143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04667143.